Ignite Creation Date:
2024-05-05 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001759
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
Status:
COMPLETED
Status Verified Date:
2000-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Asthma is a chronic inflammatory disease We propose to study inflammatory changes in the lungs of subjects with atopic asthma of different severity in vivo using positron emission tomography PET with 2-deoxy-2-18Ffluoro-D-glucose FDG It has been shown that the uptake of FDG as detected by PET scanning correlates with inflammation in animal models as well as in human disease processes such as sarcoidosis tuberculosis and abscess formation In addition it has been shown that the inflammation associated with allergen challenge in patients with atopic asthma can be visualized using PET scanning with FDG We hypothesize that the degree of FDG-uptake as a measure of inflammation correlates with the severity of asthma as determined by pulmonary function tests and clinical signs and symptoms In addition information about the spatial distribution of the inflammatory changes will be obtained To compare the characteristics of the inflammation in asthma with non-asthmatic inflammation of the lung the images obtained in asthmatic subjects will be compared with images from subjects who have inflammatory changes of the lung caused by Wegeners granulomatosis Subjects with atopic asthma and non-atopic control subjects will be selected from the community and if eligible for the study undergo skin testing against common allergens and pulmonary function testing Subjects with Wegeners granulomatosis will be selected from a large group of subjects followed with this disease at NIAID PET scanning with FDG will be used to measure inflammation in the PET scanning facility at the Clinical Center of the NIH and the results of the scanning will be correlated with the severity of the disease We expect that for the first time this methodology will permit an objective measure of the basic pathogenic process the allergic inflammation in patients with atopic asthma Using this methodology it will be possible to study the efficacy of currently available therapies for allergic inflammation In addition this methodology will provide an extremely useful tool for the development of new therapeutic approaches to the treatment of asthma
Detailed Description:
Asthma is a chronic inflammatory disease We propose to study inflammatory changes in the lungs of subjects with atopic asthma of different severity in vivo using positron emission tomography PET with 2-deoxy-2-18Ffluoro-D-glucose FDG It has been shown that the uptake of FDG as detected by PET scanning correlates with inflammation in animal models as well as in human disease processes such as sarcoidosis tuberculosis and abscess formation In addition it has been shown that the inflammation associated with allergen challenge in patients with atopic asthma can be visualized using PET scanning with FDG We hypothesize that the degree of FDG-uptake as a measure of inflammation correlates with the severity of asthma as determined by pulmonary function tests and clinical signs and symptoms In addition information about the spatial distribution of the inflammatory changes will be obtained To compare the characteristics of the inflammation in asthma with non-asthmatic inflammation of the lung the images obtained in asthmatic subjects will be compared with images from subjects who have inflammatory changes of the lung caused by Wegeners granulomatosis Subjects with atopic asthma and non-atopic control subjects will be selected from the community and if eligible for the study undergo skin testing against common allergens and pulmonary function testing Subjects with Wegeners granulomatosis will be selected from a large group of subjects followed with this disease at NIAID PET scanning with FDG will be used to measure inflammation in the PET scanning facility at the Clinical Center of the NIH and the results of the scanning will be correlated with the severity of the disease We expect that for the first time this methodology will permit an objective measure of the basic pathogenic process the allergic inflammation in patients with atopic asthma Using this methodology it will be possible to study the efficacy of currently available therapies for allergic inflammation In addition this methodology will provide an extremely useful tool for the development of new therapeutic approaches to the treatment of asthma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-I-0044 | None | None | None |